BIOACTIVE POTENTIAL OF ALOE BARBADENSIS ROOT EXTRACT INHIBITING LUNG CANCER ANGIOGENESIS

Abstract

supply for tumours, cancer cells would be deprived of nutrients and hence the cancer can be treated to greater extent. Anti-angiogenic strategies aimed
at blocking new blood vessel formation are currently emerging. The study reveals that the Aloe barbadensis contains variety of bioactive potential
compounds such as antioxidant, anti-inflammatory, anti-microbial activity and anti-angiogenetic activity. The Gas chromatography Mass spectrometric
analysis reveals that Aloe barbadensis contains nearly 276 compounds, based upon the library results. The compounds passing PK studies are allowed
to virtual screening and docking studies against Vascular Endothelial Growth Factor (VEGF) receptor. The receptor is allowed for molecular dynamics
and energy minimization before the docking, in order to get the stable and clean protein structure. The results show that the phytoconstituents in Aloe
barbadensis have more binding affinity than the commercial drugs. Escherichia coli and staphylococcus aureus shows the higher anti-microbial activity
compared to the standard antibiotic discs. The extracts are then used for chicken chrioallantoic membrane assay, in order to study the effect of the plant
extract over the growing blood vessels of the chicken embryo. This study utilised the in vitro angiogenesis assay using human lung cancer explants as
sources for angiogenetic vessel development. There is complete inhibition in the case of fractionates and partial inhibition in case of crude extracts. The
extracts are then allowed to cytotoxicity studies in A549 Lung cancer cell lines, which shows that there is no migration in the scratched area in Cancer
cell lines treated with the plant extracts. The studies reveal that the Aloe barbadensis have the anti-angiogenetic potential and can be used to reduce the
size and growth of the cancerous cells with the phytoconstituent, in order to reduce the toxicity caused by the chemotherapy agents.